drugset / Trial / NCT00120198
Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients
Phase 2
Terminated
50 enrolled
Geriatric Oncology Consortium
Tibotec Pharmaceutical Limited · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Currently there is no one standard of care for older patients with Non-Hodgkin's Lymphoma (NHL). The study will examine the tolerability and feasibility to the combination of Cyclophosphamide, Pegylated Liposomal Doxorubicin, Vincristine, Prednisone (CDOP) plus Rituximab.
Timeline
- Start
- 2005-03
- Primary completion
- —
- Completion
- 2006-09
Outcome
Outcome not reported
Stopped (Enrollment): “slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Prednisone | Other / unclassified | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |
| Subject | Vincristine | Small molecule | — | — |